Israel - hebraico - Ministry of Health

taro international ltd, israel - dimethyl fumarate - dimethyl fumarate 120 mg - dimethyl fumarate

Israel - hebraico - Ministry of Health

taro international ltd, israel - dimethyl fumarate - dimethyl fumarate 240 mg - dimethyl fumarate

Israel - hebraico - Ministry of Health

medomie pharma ltd, israel - teriflunomide - טבליות מצופות פילם - teriflunomide 14 mg - teriflunomide

Israel - hebraico - Ministry of Health

taro international ltd, israel - teriflunomide - טבליות מצופות פילם - teriflunomide 14 mg - teriflunomide

Israel - hebraico - Ministry of Health

comex ltd - cefalexin as sodium - תרחיף להזרקה - cefalexin as sodium 180 mg/ml - cefalexin

Israel - hebraico - Ministry of Health

hanna drugstore f.a. - salicylic acid - מדבקות - salicylic acid 40 % - salicylic acid - salicylic acid - for the treatment of hard skin on the sole of the foot.

Israel - hebraico - Ministry of Health

hanna drugstore f.a. - salicylic acid - מדבקות - salicylic acid 40 % - salicylic acid - salicylic acid - keratolytic for the removal of corn.

Israel - hebraico - Ministry of Health

glaxo smith kline (israel) ltd - mupirocin as calcium - משחה - mupirocin as calcium 2 %w/w - mupirocin - mupirocin - the elimination of nasal carriage of staphylococci, including methycillin-resistant staphylococus aureus (mrsa).

Israel - hebraico - Ministry of Health

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

Israel - hebraico - Ministry of Health

bayer israel ltd - moxifloxacin - תמיסה לאינפוזיה - moxifloxacin 400 mg / 250 ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.